Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: A prospective randomised trial

Heart

Volumn 83, Issue 5, 2000, Pages 551-556

  Heintzen, M P ^a   Heidland, U E ^a   Klimek, W J ^a   Leschke, M ^a   Kelm, M ^a   Schwartzkopff, B ^a   Vester, E G ^a   Michel, C J ^a   Strauer, B E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Abrupt vessel closure; Dipyridamole; Percutaneous transluminal coronary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; HEPARIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK MANAGEMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034102766     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.83.5.551     Document Type: Article

References (32)

1. Detre KM, Holmes DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: The 1985-1986 National Heart, Lung and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 1990;82:739-50.
2. Feyter de PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 1991;83: 927-36.
3. Heintzen MP, Motz W, Leschke M, et al. Akuter Koronargefäßverschluß nach elektiver perkutaner transluminaler Koronarangioplastie: Inzidenz und Therapie bei 5000 konsekutiven Patienten. Dtsch Med Wschr 1994;119: 1023-8.
4. The Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-95.
5. The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
6. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection Circulation 1990;82: 1193-202.
7. Mabin TA, Holmes DR, Smith HC, et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5:198-202.
8. Chesler E, Gornick C, Pierpont G, et al. High incidence of acute coronary occlusions complicating percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 1989;15:665-7.
9. Feyter de PJ, Serruys PW, vd Brand M, et al. Percutaneous transluminal coronary angioplasty for unstable angina. Am J Cardiol 1991;68:125B-35B.
10. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
11. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989;14:813-36.
12. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
13. Merino A, Cohen M, Badimon JJ, et al. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994;24:1091-4.
14. Lembo NJ, Black AJR, Roubin GS, et al. Effect of pretreatment with aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422-6.
15. Danchin N, Juilliere Y, Kettani C, et al. Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty. Am Heart J 1994;127:494-8.
16. Kübier W. Die Bindung des Koronardilatators Dipyridamol an die Plasmaeiweißkörper des Menschen. Arch Kreislaufforsch 1971;64:115-26.
17. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-14.
18. Heintzen MP, Motz W, Leschke M, et al. PTCA im Stadium des akuten Myokardinfarktes: Hospitalverlauf von 783 konsekutiven Patienten. Z Kardiol 1994;83:404-13.
19. Strauer BE, Heidland UE, Vogt M, et al. Protektion und "Preconditioning" des menschlichen Herzens während perkutaner transluminaler Koronarangioplastie (PTCA) durch Dipyridamol intrakoronar. Med Klinik 1995;90:125-30.
20. Strauer BE, Heidland UE, Heintzen MP, et al. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 1996;28:1119-26.
21. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76: 125-34.
22. Emmons PR, Harrison MJG, Honour AJ, et al. Effect of dipyridamole on human platelet behaviour. Lancet 1965;ii: 603-6.
23. Fitzgerald GA. Drug therapy: dipyridamole. N Engl J Med 1987;316:1247-57.
24. Mills DCB. The role of cyclic nucleotides in platelets. In: Kebabian JW, Nathanson JA, eds. Cyclic nucleotides: Part II: physiology and pharmacology. Berlin: Springer Verlag, 1982:723-61.
25. Moncada S, Korbut R. Dipyridamole and other pnosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978;i:1286-9.
26. German DC, Kredich NM, Bjornsson TD. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989;45:80-4.
27. Kübler W, Spieckermann PG, Bretschneider HJ. Influence of dipyridamole (Persantin) on myocardial adenosine metabolism. J Mol Cell Cardiol 1970;1:23-37.
28. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990;70:761-845.
29. Schrader J, Berne RM, Rubio T. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 1972;223:159-65.
30. Haslam RJ, Lynham JA. Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloradenosine. Life Sci 1972;11(pt 2):1143-54.
31. Dawicki DD, Agarwal KC, Parks RE. Role of adenosme uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine Biochem Pharmacol 1985;34:3965-72.
32. Buchanan MR, Rosenfeld J, Gent M, et al. Increased dipyridamole plasma concentrations associated with salicylate administration: relationship to effects on platelet aggregation in vivo. Thromb Res 1979;15:813-20.